Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1–3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis
Authors:
Open Access
- 23 May 2026
- journal article
- Published by Springer Nature in Breast Cancer
- Vol. 33 (4) , 928-937
Abstract
The monarchE trial enrolled patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC). Although both macrometastasis and micrometastasis were eligible, the number of patients with only micrometastasis was not reported, leaving their prognosis uncertain. This study compared outcomes of patients with 1-3 positive axillary lymph nodes (pALNs), including those with only micrometastases and those with macrometastases, according to monarchE high-risk criteria. We retrospectively reviewed 844 patients with HR-positive/HER2-negative/node-positive EBC from a prospectively maintained institutional database and classified them into four groups: Group 1, 1-3 pALNs (including macrometastasis) with grade 3 tumors or tumors ≥ 5 cm; Group 2, 1-3 pALNs (only micrometastasis) with grade 3 tumors or tumors ≥ 5 cm; Group 3, 1-3 pALNs (including macrometastasis) with grade < 3 tumors and tumors < 5 cm; and Group 4, 1-3 pALNs (only micrometastasis) with grade < 3 tumors and tumors < 5 cm. Invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) were analyzed using the Kaplan-Meier method and log-rank test. Univariable Cox models assessed associations between clinical factors and outcomes. Group 2 showed outcomes comparable to Group 1 (5-year IDFS: 80.7% vs. 83.7%; DRFS: 89.5% vs. 87.9%). In univariate analysis, only tumor size-rather than Group 2 or histological grade-was prognostic for IDFS and DRFS. Sensitivity analyses restricted to patients undergoing axillary lymph node dissection yielded consistent results. Among HR-positive/HER2-negative EBC, high-risk patients with only micrometastasis demonstrated prognoses similar to those with macrometastasis.Keywords
This publication has 17 references indexed in Scilit:
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trialThe Lancet Oncology, 2022
- De-escalating Locoregional Therapy for Axillary Micrometastases in Breast Cancer: How Much is Too Much?Clinical Breast Cancer, 2022
- Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary TherapyBreast Cancer Research and Treatment, 2021
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Journal of Clinical Oncology, 2020
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateJournal of Clinical Oncology, 2020
- Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trialThe Lancet Oncology, 2018
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 StatusJNCI: Journal of the National Cancer Institute, 2014
- The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancerBreast Cancer, 2010
- Impact of Micrometastases in the Sentinel Node of Patients With Invasive Breast CancerJournal of Clinical Oncology, 2009
- Micrometastases or Isolated Tumor Cells and the Outcome of Breast CancerNew England Journal of Medicine, 2009